2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13C.02 High-Dose Radiation Therapy for Limited-Stage Small-Cell Lung Cancer: Real-World Experience from Two Tertiary Centers

EP.13C.02 High-Dose Radiation Therapy for Limited-Stage Small-Cell Lung Cancer: Real-World Experience from Two Tertiary Centers

Back to course

Pdf Summary

This document reports a retrospective analysis of high-dose radiation therapy for limited-stage small-cell lung cancer (LS-SCLC) conducted at two tertiary centers in Israel from 2020 to 2024. The treatment involved a concurrent chemo-radiotherapy regimen utilizing high-dose, twice-daily radiation therapy (60 Gy in 40 fractions over four weeks). The study aimed to evaluate real-world outcomes and was based on results from a recent phase 2 study highlighting the benefits of radiation dose escalation in LS-SCLC.<br /><br />The patient cohort consisted of 13 individuals with a median age of 59 years, predominantly female (61.5%). The majority had advanced stages of cancer, with the most patients presenting at stage IIIB. Treatment completion was high, with 92.3% of patients finishing the radiation therapy. The response rates to the treatment were promising, showing an overall response in 61.5% of patients, with 46.1% achieving complete response and 15.4% partial response. However, 23% of the patients experienced disease progression.<br /><br />The median overall survival was reported at 30.9 months, with a median progression-free survival of 9.1 months. The treatment exhibited a reasonable toxicity profile, particularly when compared to previous trials. Notably, severe (grade 3-4) esophagitis and neutropenia were observed in 7.6% and 38.4% of patients, respectively, with no patients experiencing grade 5 events.<br /><br />The findings suggest that high-dose radiation therapy for LS-SCLC results in excellent local control, promising response rates, favorable early survival outcomes, and manageable toxicity levels. The study's insights are aligned with prior research such as the ADRIATIC trial, underscoring the need for further prospective trials to validate these results. Overall, the real-world application of this regimen demonstrates promising potential in the clinical setting, although further research is necessary for broader adoption.

Asset Subtitle

Oded Icht

Meta Tag

Speaker Oded Icht

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

high-dose radiation therapy

limited-stage small-cell lung cancer

LS-SCLC

chemo-radiotherapy

real-world outcomes

radiation dose escalation

treatment response rates

progression-free survival

toxicity profile

ADRIATIC trial